Interferon gamma - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Interferons

Included in the formulation

Ingarone®

lyophilizate nazal.

NPP FARMAKLON, LLC Russia

Ingarone®

lyophilizate w / m PC

NPP FARMAKLON, LLC Russia

Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

VED

АТХ:

L.03.A.B.03 Interferon Gamma

Pharmacodynamics:

Interferon gamma (immune interferon) is the most important anti-inflammatory cytokine, the producers of which in the human body are natural killer cells, CD4 Th1 cells and CD8 cytotoxic suppressor cells. Receptors for interferon gamma have macrophages, neutrophils, natural killer cells, cytotoxic T-lymphocytes. Interferon Gamma activates the effector functions of these cells, in particular their microbicide, cytotoxicity, their production of cytokines, superoxide and nitroxide radicals, thereby causing the death of intracellular parasites. Interferon Gamma inhibits the B-cell response to interleukin-4, suppresses IgE production and CD23 antigen expression. It is an inducer of apoptosis of differentiated B cells, giving rise to autoreactive clones. Suppresses the suppressive effect interleukin-4 for interleukin-2-dependent proliferation and generation of lymphokine-activated killers. Activates the production of proteins of the acute phase of inflammation, enhances the expression of C₂ and C₄ components of the complement system.

Unlike other interferons, it increases the expression of antigens of the main histocompatibility complex of both 1st and 2nd classes on different cells, and induces the expression of these molecules even on those cells that do not express them constitutively. This improves the efficiency of antigen presentation and the ability to recognize them by T lymphocytes.

Interferon gamma blocks the replication of viral DNA and RNA, the synthesis of viral proteins and the assembly of mature viral particles. Interferon Gamma has a cytotoxic effect on virus-infected cells.

Interferon gamma blocks the synthesis of β-TGF, responsible for the development of pulmonary fibrosis and liver.

Pharmacokinetics:

It is not adsorbed through the digestive tract. Peak concentrations in plasma - 4 hours after intramuscular injection; 7 hours after subcutaneous. Half-life - 38 minutes with intravenous injection, 2.9 hours - with intramuscular and 5.9 hours - with subcutaneous injection.

Indications:

Lyophilizate for the preparation of solution for intramuscular and subcutaneous administration

Complex therapy:

- chronic viral hepatitis C;

- chronic viral hepatitis B;

- HIV/AIDS infection;

- pulmonary tuberculosis;

- mycobacterial infection in HIV-negative patients with ineffective conservative therapy;

- Oncological diseases (as an immunomodulator - including in combination with chemotherapy);

urogenital chlamydia;

- chronic prostatitis;

- genital herpesvirus infection and herpes zoster (Herpes zoster) - in monotherapy;

- psoriasis;

- Rhematoidth arthritis;

- limphogranulomatosis;

- Visceral leishmaniasis;

- leprosy;

- eczema and atopic dermatitis;

- Anogenital warts (human papilloma virus) - treatment and prevention of recurrence of the disease.

Prevention infectious complications in patients with chronic granulomatous disease.

Liofilizate for the preparation of solution for intranasal administration

Complex therapy in the prevention and treatment of influenza and influenza "bird-like" (H₅N₁ and H₁N₁).

ICD-10

I.A15-A19.A16 Tuberculosis of respiratory organs, not confirmed bacteriologically or histologically

I.A30-A49.A30 Leprosy [Hansen's disease]

I.A30-A49.A31.0 Pulmonary infection caused by Mycobacterium

I.A50-A64.A56 Other chlamydial diseases, sexually transmitted diseases

I.A50-A64.A60 Anogenital herpetic viral infection [herpes simplex]

I.A50-A64.A63.0 Anogenital (venereal) warts

I.B00-B09.B02 Shingles [herpes zoster]

I.B15-B19.B18.0 Chronic viral hepatitis B with delta-agent

I.B15-B19.B18.1 Chronic viral hepatitis B without delta-agent

I.B15-B19.B18.2 Chronic viral hepatitis C

I.B20-B24 Disease caused by the human immunodeficiency virus [HIV]

I.B50-B64.B55 Leishmaniasis

II.C76-C80.C80 Malignant neoplasm without specification of localization

II.C81-C96.C81 Hodgkin's disease [lymphogranulomatosis]

XII.L20-L30.L20.8 Other atopic dermatitis

XII.L40-L45.L40 Psoriasis

XII.L80-L99.L92 Granulomatous changes in the skin and subcutaneous tissue

XIII.M05-M14.M05 Seropositive rheumatoid arthritis

XIV.N40-N51.N41.1 Chronic prostatitis

XIV.N70-N77.N74.4 * Inflammatory diseases of female pelvic organs caused by chlamydiae (A56.1 +)

Contraindications:

Common for both dosage forms:

- individual intolerance to interferon gamma or any other component of the drug;

- Pregnancy.

Lyophilizate for solution for intramuscular and subcutaneous administration:

- autoimmune diseases;

- diabetes;

- violations of the cardiovascular system (ischemia, cardiovascular failure, arrhythmia);

- violations from the central nervous system (epileptic seizures);

- multiple sclerosis;

- Systemic syphilis;

- simultaneous use with cytostatic drugs and radiation therapy.

Liofilizate for the preparation of solution for intranasal administration: children's age is less than 7 years.

Carefully:

No data.

Pregnancy and lactation:

Recommendations FDA category C. The drug is contraindicated in pregnancy. There is no information on the penetration into breast milk. Do not apply!

Dosing and Administration:

The dosage regimen is set individually.

Intramuscularly, subcutaneously. The contents of the vial are dissolved in 2 ml of water for injection. The dose of the drug is set individually.

For the treatment of patients with chronic viral hepatitis B, chronic viral hepatitis C, and HIV-infection /AIDS and pulmonary tuberculosis the average daily intake for adults is 500,000 ME. It is administered 1 time per day, daily or every other day. The course of treatment is from 1 to 3 months, if necessary, after 1-2 months, the course of treatment is repeated.

For the prevention of infectious complications in patients with chronic granulomatous disease usually the average daily intake for adults is 500,000 IU. It is administered 1 time per day, daily or every other day.On the course - 5-15 injections, if necessary, the course is prolonged or repeated after 10-14 days.

For the treatment of oncological diseases the average daily intake for adults is 500,000 ME. Introduced once a day, every other day.

For the treatment of genital herpesvirus infection, herpes zoster (Herpes zoster) and urogenital chlamydia the average daily intake for adults is 500,000 IU. Introduced once a day subcutaneously, in one day. The course of treatment is 5 injections.

For the treatment of chronic prostatitis daily dose is 100 000 IU. Introduced once a day subcutaneously, in one day. The course of treatment is 10 injections.

For the treatment of anogenital warts daily dose is 100 000 IU. Introduced once a day subcutaneously, after a cryodestruction, every other day. The course of treatment is 5 injections.

Intranasally. The contents of the vial are dissolved in 5 ml of water for injection.

At the first signs of the flu, ARVI - 2 drops in each nasal passage, after the toilet of the nasal passages, 5 times a day for 5-7 days.

For prevention ARVI and influenza in contact with the patient and / or under hypothermia - 2-3 drops in each nasal pass every other day for 30 minutes before breakfast for 10 days. If necessary, preventive courses are repeated.When a single contact is enough, one instillation.

After instillation it is recommended to massage the wings of the nose with your fingers for several minutes to distribute the drug evenly in the nasal cavity.

Side effects:

Grippopodobny syndrome, aboutchills, thefatigue, fromoneness, tnausea, PAn increase in the activity of transaminases, toItching, atGreat fever, myialgii, fromlaboriousness, Pweight loss, Mr.etiropenia and thrombocytopenia, aLopezia, Pan oligomorphic rash.

Overdose:

Not described. Treatment is symptomatic.

Interaction:

Not described.

Special instructions:

In case of severe side effects, stop taking the drug.

Impact on the ability to manage motor transport and other technical devices

Not found.

Instructions

Interferon Gamma (Interferonum gamma)